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| INTRODUCTION
Warfarin is commonly used to prevent stroke among patients with atrial fibrillation and to prevent recurrent venous thromboembolism.
However, due to complex pharmacokinetic properties and multiple drug-drug and drug-food interactions, warfarin's in vivo effect is 
| METHODS
At four large telephone-based anticoagulation management services in the state of Michigan, patients newly starting warfarin therapy were randomly selected and followed as part of a Blue Cross 
| Phase 2. Prospective data collection
Trained research assistants spent a total of 8. 
Essentials
• Out-of-range INR values are common for warfarin-treated patients.
• Phone-based anticoagulation clinics commonly manage a large number of warfarin-treated patients.
• Out-of-range INR values requires an average of 2.2 minutes more staff time than in-range INRs.
• Out-of-range INRs required an average of nearly $18 000 additional staff costs annually.
| Statistical analysis
The frequencies of contacts for each group were summarized using descriptive statistics (adjusted mean, median, and interquartile range [IQR]) as well as compared using Poisson regression. telephone calls and voicemail messages, with fewer mailed letters.
| Cost estimates
Overall, OOR INR patients were more often associated with multiple methods of contact than consistently in-range INR patients (83.6% vs 55.2%, P < .001).
The average number of contacts by nursing and pharmacist staff did not differ between the OOR and in-range INR patients (Table 2) .
However, there were more contacts by administrative assistants for the OOR patients as compared to in-range patients (adjusted means 
| Phase 2: Prospective data collection
Interactions between patients and anticoagulation clinic staff related to managing 59 OOR INR patients and 92 control patients were observed during the prospective study period. Length of warfarin treatment was similar for the two groups (mean ± SD 3. 
| Cost estimates
The Other studies have explored the impact of cost from societal, payer, and patient perspectives as well as comparing various methods of INR management. 5, 6 Another study compared the costs of warfarin management in patients with and without bleeding events, noting increased costs associated with bleeding. 7 However, none of these studies has explicitly outlined the health-care utilization bur- practice for patients taking a DOAC. [8] [9] [10] [11] [12] [13] [14] [15] [16] To help address this concern, the European Heart Rhythm Association recommends clinical follow up of DOAC-treated patients at least every 6 months, but suggests that every 1-3 months may be appropriate for many patients. 17 This important contact between the patient and the health-care system can be performed by primary care providers, specialists, or an anticoagulation clinic. In fact, the anticoagulation clinic may be ideally structured to provide this ongoing monitoring and support for patients, regardless of the oral anticoagulant they are currently prescribed. 18 Our study has important strengths, including the use of trained chart abstractors to detail any and all documented contact between patients and the anticoagulation clinic. This study is also strengthened by the multi-center design. Finally, the salaries used reflect real world data, but also are very similar to national salary figures published by the Bureau of Labor Statistics. 19 However, important limitations must be considered. These include limited geographic range of the four involved healthcare centers as well as the focus on anticoagulation clinic care as compared to care provided by individual physician offices and their staff. Additionally, while dosing protocols exist at each center, the individual nurse or pharmacist is able to determine the most appropriate management strategy based on their knowledge of the patients, their clinical experience, and the guidance of the clinic protocols. Finally, the anticoagulation staff were aware that the study team was monitoring and measuring their practice, which could have influenced how quickly they delivered care.
In summary, we have quantified the additional staff effort required to manage patients on chronic warfarin therapy who experience a single OOR INR value without associated bleeding or thromboembolic complications, which leads to increased healthcare system utilization. Optimizing anticoagulation clinic resource utilization with patient expectations and clinical outcomes remains an important goal for further study.
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